MYMasafumi Yamada

Masafumi Yamada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masafumi Yamada has a total of 150 co-authors. Here are the top co-authors by number of shared publications:

  • Tadashi Ariga

    Department of Pediatrics Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan

    8 shared publications
  • Masahiro Ueki

    Department of Pediatrics, https://ror.org/02e16g702Graduate School of Medicine, Hokkaido University, Sapporo, Japan

    6 shared publications
  • Yusuke Tozawa

    Department of Pediatrics Division of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan

    5 shared publications
  • Ichiro Kobayashi

    Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    4 shared publications
  • Ichiro Kobayashi

    Center for Pediatric Allergy and Rheumatology KKR Sapporo Medical Center Sapporo Japan

    3 shared publications
  • Shimaa Said Mohamed Ali Abdrabou

    Department of Pediatrics Division of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan

    3 shared publications

Latest Publications

  • Open Access

    Nationwide TREC/KREC-based newborn screening and clinical outcomes in Japan

    by Tsubasa Nishinosono, Hideki Muramatsu, Manabu Wakamatsu, Nobuyuki Ishige, Junji Hanai, Takahiro Imaizumi, Masahiro Ueki, Yoji Sasahara, Toshinao Kawai, Yoji Uejima, et al.

    Large-scale real-world data on T-cell receptor excision circle (TREC)– and κ-deleting recombination excision circle (KREC)–based newborn screening for inborn errors of immunity remain limited. In this nationwide cohort, we evaluated Japan’s program (2020–2025), including 1,380,634 newborns. Of 869 referred infants (0.06%), 40 were diagnosed, including 15 with severe combined immunodeficiency (SCID), 16 with X-linked agammaglobulinemia or other agammaglobulinemias, and nine with severe T cell lymphopenia. After a median follow-up of 18 mo, overall survival was 98%. All infants with SCID survived; 14 underwent hematopoietic cell transplantation with sustained engraftment. Referral rates were 0.04% for TREC and 0.03% for KREC. Repeat sampling was associated with lower referral rates (0.05 vs. 0.56%). Referral rates varied across assay kits and laboratory practices, reflecting interlaboratory heterogeneity in a decentralized screening system. The transition from self-paid to public funding increased coverage from 77.1 to 97.7%. These findings support TREC/KREC-based screening and highlight the need for standardized algorithms and sustained public funding for equitable nationwide implementation.


  • Open Access

    A de novo dominant-negative variant is associated with OTULIN-related autoinflammatory syndrome

    by Yukiko Takeda, Masahiro Ueki, Junpei Matsuhiro, Erik Walinda, Takayuki Tanaka, Masafumi Yamada, Hiroaki Fujita, Shunichiro Takezaki, Ichiro Kobayashi, Sakura Tamaki, et al.

    OTULIN-related autoinflammatory syndrome (ORAS), a severe autoinflammatory disease, is caused by biallelic pathogenic variants of OTULIN, a linear ubiquitin-specific deubiquitinating enzyme. Loss of OTULIN attenuates linear ubiquitination by inhibiting the linear ubiquitin chain assembly complex (LUBAC). Here, we report a patient who harbors two rare heterozygous variants of OTULIN (p.P152L and p.R306Q). We demonstrated accumulation of linear ubiquitin chains upon TNF stimulation and augmented TNF-induced cell death in mesenchymal stem cells differentiated from patient-derived iPS cells, which confirms that the patient has ORAS. However, although the de novo p.R306Q variant exhibits attenuated deubiquitination activity without reducing the amount of OTULIN, the deubiquitination activity of the p.P152L variant inherited from the mother was equivalent to that of the wild-type. Patient-derived MSCs in which the p.P152L variant was replaced with wild-type also exhibited augmented TNF-induced cell death and accumulation of linear chains. The finding that ORAS can be caused by a dominant-negative p.R306Q variant of OTULIN furthers our understanding of disease pathogenesis.


  • Absent X‐linked inhibitor of apoptosis protein expression in T cell blasts and causal mutations including non‐coding deletion

    by Shimaa Said Mohamed Ali Abdrabou, Nariaki Toita, Shin Ichihara, Yusuke Tozawa, Michiko Takahashi, Shin‐Ichi Fujiwara, Toshifumi Ashida, Osamu Ohara, Tadashi Ariga, Atsushi Manabe, et al.

    Background: X‐linked inhibitor of apoptosis protein (XIAP) deficiency is one of inborn errors of immunity characterized by recurrent hemophagocytic lymphohistiocytosis and refractory inflammatory bowel disease (IBD), mimicking Crohn’s disease. The aim of this study is to make an accurate diagnosis of XIAP deficiency based on genetic and XIAP expression studies and to investigate endoscopic findings shared by patients with this disease. Methods: Four male patients with recurrent hemophagocytic lymphohistiocytosis and long‐term refractory IBD were studied for the diagnosis of XIAP deficiency. Endoscopic findings of the four patients were also studied in parallel. Results: These four patients were diagnosed with XIAP deficiency based on the absent XIAP expression in cultured T‐cell blasts. Sequence analysis of the responsible gene, XIAP , demonstrated two novel nonsense mutations of p.Gln114X and p.Glu25X, and a previously reported nonsense mutation of p.Arg381X. Although no mutations in the coding region were detected in the fourth patient, further studies demonstrated a novel 2,199 bp deletion encompassing non‐coding exon 1, presumably affecting transcription and stability of XIAP mRNA. All of the patients eventually underwent hematopoietic stem cell transplantation, leading to a complete or partial remission of IBD. These four patients shared an endoscopic finding of multiple wide and longitudinal ulcers with straight and non‐raised edge in the colon. Conclusions: X‐linked inhibitor of apoptosis protein expression in T‐cell blasts could facilitate the diagnosis of this disease, especially with causal mutations in non‐coding regions.

  • Open Access

    Nonconditioned ADA-SCID gene therapy reveals ADA requirement in the hematopoietic system and clonal dominance of vector-marked clones

    by Toru Uchiyama, Sirirat Takahashi, Kazuhiko Nakabayashi, Kohji Okamura, Kaori Edasawa, Masafumi Yamada, Nobuyuki Watanabe, Emi Mochizuki, Toru Yasuda, Akane Miura, et al.


  • Open Access

    Progressive multifocal leukoencephalopathy with mild clinical conditions and detection of archetype-like JC virus in cerebrospinal fluid

    by Kosuke Iwami, Kazuo Nakamichi, Masaaki Matsushima, Azusa Nagai, Shinichi Shirai, Sho Nakakubo, Ikuko Takahashi-Iwata, Masafumi Yamada, Ichiro Yabe

    Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system with a poor prognosis and is primarily caused by JC virus (JCV) with a mutation called prototype. We encountered a case of PML with moderate progression and analyzed the mutational patterns of JCV in the cerebrospinal fluid (CSF). A 19-year-old Japanese woman with mild neurological symptoms was diagnosed with combined immunodeficiency following pneumocystis pneumonia. Brain magnetic resonance imaging scan showed multiple brain lesions, and real-time polymerase chain reaction testing detected JCV in the CSF, leading to the diagnosis of PML. The disease course of PML was stable after administration of mefloquine and mirtazapine with immunoglobulin replacement therapy. In the JCV genome cloned from the patient CSF, DNA sequences of the gene encoding the capsid protein (VP1) and the non-coding control region exhibited small mutations. However, they were quite similar to those of the archetype JCV, which persists asymptomatically in healthy individuals. These findings provide insight into the mutational characteristics of JCV in PML with mild symptoms and progression.


  • Open Access

    Neonatal lupus erythematosus with diffuse iron deposition in the liver on magnetic resonance imaging

    by Yuto Suzuki, Yutaka Uzuki, Hirotaka Kato, Kyohei Kudo, Satoshi Yakuwa, Takashi Nasu, Kimiaki Uetake, Masafumi Yamada

    Rationale: Neonatal lupus erythematosus (NLE) is caused by transplacental transfer of maternal autoantibodies against SS-A, SS-B, and/or RNP. Symptoms include heart block, skin lesions, cytopenia, liver dysfunction, and occasionally hydrocephalus. Hepatobiliary disease in NLE should be closely monitored, since severe liver failure has been reported. Patient concerns: A 0-day-old female patient presented with nonspecific systemic erythema, liver dysfunction, and hyperferritinemia at birth, and abdominal magnetic resonance imaging indicated diffuse iron deposition in the liver but not in extrahepatic tissues. The patient had no maternal complications or findings indicating intrauterine growth retardation, oligohydramnios, or fetal ascites. Diagnoses: The patient was diagnosed with NLE based on the presence of anti-SS-A and SS-B antibodies in the maternal and cord blood. Interventions: No intervention was required. Outcomes: Her symptoms improved spontaneously. The titers of anti-SS-A and SS-B antibodies became undetectable levels on day 379, while serum anti-double stranded DNA antibody became positive without any clinical symptoms. Lessons: Since NLE with hepatobiliary disease could present with diffuse iron deposition in the liver mimicking neonatal hemochromatosis, we need to carefully evaluate and monitor this condition.

  • A deep intronic mutation of c.1166-285 T > G in SLC46A1 is shared by four unrelated Japanese patients with hereditary folate malabsorption (HFM)

    by Yusuke Tozawa, Shimaa Said Mohamed Ali Abdrabou, Natsuko Nogawa-Chida, Ritsuo Nishiuchi, Toshiaki Ishida, Yuichi Suzuki, Hideki Sano, Ryoji Kobayashi, Kenji Kishimoto, Osamu Ohara, et al.


  • CONSIDERATION ON SOCIAL CHARACTERISTICS OF FREQUENTLY FLOODED AREAS IN JAPAN FOCUING ON GEOGRAPHY AND POPULATION TREND

    by Yuka Muto, Satoshi Watanabe, Masafumi Yamada, Takeyoshi Chibana

    水害常襲地とその周辺部の社会特性を,地形特性との関係を考慮しながら解明することは,地域特性に応じた土地利用や治水整備のあり方を検討する上で重要である.本研究では水害常襲地を含む行政区の地形分類を行い,地形分類ごとの人口動態の違いを分析した.その結果,人口密度と人口変化率は地形分類ごとに偏りがあった.さらに,地形図判読や視察による詳細な検討により,中小河川・平地型では都市の拡大による浸水リスクの増大がある,中小河川・狭隘型では宅地から離れた人的経済的被害の少ない区域が浸水している,大河川・狭隘型と中間型では新たな治水整備の進行や遊水地的な利用による浸水域の形成がある,というように,地形分類ごとに水害常襲地の社会的特徴の違いがあることがわかった.


  • Evaluation of systemic activity of pediatric primary Sjögren’s syndrome by EULAR Sjögren’s syndrome disease activity index (ESSDAI)

    by Ichiro Kobayashi, Yuka Okura, Masahiro Ueki, Yusuke Tozawa, Shunichiro Takezaki, Masafumi Yamada, Tadashi Ariga

    Objectives: The purpose of this study is to evaluate systemic disease activity of pediatric Sjögren’s syndrome (SS) using European League Against Rheumatism (EULAR) Sjögren’s syndrome disease activity index (ESSDAI). Methods: We retrospectively reviewed medical records of patients with SS who have been diagnosed according to 1999 Japanese diagnostic criteria for SS before 16 years old at KKR Sapporo Medical Center, Hokkaido University Hospital, and affiliated hospitals. We analyzed clinical and laboratory data and calculated ESSDAI at both diagnosis and peak activity. Results: Twenty-five patients (2 boys and 23 girls) were enrolled. Only 4 patients had sicca symptoms at diagnosis. Mean ESSDAI scores at diagnosis and peak activity were 12.68 (2–31) and 15.08 (2–38), respectively. Only 3 patients were inactive (ESSDAI score <5) at diagnosis. Frequently involved domains at diagnosis were the biological (96%) followed by the constitutional (68%), glandular (44%), articular (44%), cutaneous domains (28%), renal (16%), and central nervous system (12%). At peak activity, biological domain (96%) was followed by the constitutional (72%), glandular (60%), articular (44%), cutaneous (28%), central nervous system (20%), and renal domains (16%). Conclusion: Pediatric SS is suspected from active systemic manifestations. The items of ESSDAI are useful clues to the diagnosis of pediatric SS.


  • Difficulty in the diagnosis of bone and joint pain associated with pediatric acute leukemia; comparison with juvenile idiopathic arthritis

    by Takao Tsujioka, Minako Sugiyama, Masahiro Ueki, Yusuke Tozawa, Shunichiro Takezaki, Junjiro Ohshima, Yuko Cho, Masafumi Yamada, Akihiro Iguchi, Ichiro Kobayashi, et al.

    Acute leukemia often causes osteoarthralgia. The aim of this study is characterization of leukemia-associated osteoarthralgia in comparison with juvenile idiopathic arthritis (JIA). We retrospectively reviewed clinical records of 31 patients with acute leukemia and 13 patients with articular JIA diagnosed between January 2008 and March 2013. Clinical and laboratory findings at the initial examination were compared among the three groups; 10 leukemia with and 21 leukemia without osteoarthralgia and 13 JIA groups. Eleven of the 31 leukemic patients (35%) had osteoarthralgia before the diagnosis of leukemia. Peripheral leukemic cells were initially absent in 10 of the 31 leukemia patients including three with osteoarthralgia. Platelet counts over 300 × 109/L were common in JIA, but not in osteoarthralgia group. Mean serum lactate dehydrogenase levels were higher in both of the leukemia groups than JIA group but often within normal or near-normal levels in the leukemia groups. Magnetic resonance imaging was examined in three leukemic patients and demonstrated osteomyelitis-like bone marrow edema in two and periarticular infiltration similar to synovitis in one patient. Three leukemic patients with osteoarthralgia showed partial and transient responses to antibiotic therapy. Leukemia-associated osteoarthralgia is often indistinguishable from rheumatic diseases by imaging and laboratory findings and should be confirmed by bone marrow examination.